Home » news »

Improving a approach we allot prostate cancer treatment

 

May-Britt Tessem’s investigate organisation during a Norwegian University of Science and Technology has already rescued metabolic markers in blood that can apart prostate cancer from soft prostatic hyperplasia. Now a European Research Council has awarded Tessem a EUR 1.5 million extend to continue her research. Credit: Geir Otto Johansen, St. Olavs Hospital, Trondheim

Prostate cancer is a many common cancer among organisation in Europe. Every year around 5000 organisation in Norway are diagnosed with a disease.

Many opposite forms of prostate cancer can't be renowned yet. Researchers have lacked a evidence collection to accurately compute a assertive forms from a reduction assertive types.

Some patients need assertive diagnosis of a disease, though this isn’t always necessary. The inability to consider a border of a cancer leads to many people being overtreated and successive pang from nonessential ailments.

A Trondheim-based investigate organisation during a Norwegian University of Science and Technology (NTNU) wants to do something about this. Researcher May-Britt Tessem is streamer adult a team, that is dependent with a MR Cancer Group during NTNU’s Department of Circulation and Medical Imaging.

The European Research Council, dependent with a EU, is so tender with a work of a Tessem Group that Tessem has been awarded a prestigious European Research Council (ERC) Starting Grant for her investigate on prostate cancer.

Distinguishing high-risk cancer forms

Tessem is conducting simple investigate on prostate cancer. The investigate organisation is operative on MR prostate imaging.

The organisation wants to find clinical evidence markers that can assistance forestall overtreatment with a attendant side effects and reduced peculiarity of life. At a same time, a researchers wish to brand a many high-risk cases.

To this end, Tessem and her colleagues aim to yield information about a molecular signature of any patient.

New technology

In a investigate plan upheld by a EU, Tessem is changeable from study one form of cancer in a dungeon line to retrieving hankie from prostate cancer patients in vital hankie biobanks.

“To do this, we’ll be regulating new and groundbreaking imaging technology, called ‘multi-omics technology’,” she pronounced .

May-Britt Tessem, a researcher during a Norwegian University of Science and Technology, is operative with hankie samples from a operation of timeless Norwegian biobanks in her query to improved know prostate cancer. Credit: Geir Otto Johansen, St. Olavs Hospital, Trondheim

The new record enables a three-dimensional overview of a hankie and what it consists of.

The record will be used on one and a same hankie representation from around 1000 patients. These samples come from high peculiarity biobanks during NTNU and St. Olavs Hospital: MR Biobank, Biobank 1 and MRI-Guided Biopsies.

On a trail to a solution

Tessem’s organisation is building on one of a new discoveries. The organisation has rescued dual metabolic biomarkers, that are substances in a physique that can be analyzed and that tell us something about a condition of a body.

These dual sold biomarkers can exhibit information about prostate cancer. The biomarkers seem to establish either prostate cancer patients are expected to relapse after surgery, so they can be critical markers for assertive prostate cancer.

The markers can make it easier to detect a life-threatening forms of prostate cancer that need quick and personalized treatment. These can be rescued before receiving diagnosis in an MRI scanner.

This process could turn an critical trail to building new medications.

The British Journal of Cancer has supposed and will shortly tell a investigate group’s findings.

Big consequences

The miss of good evidence tools has vital consequences. Patient exams engage a risk of infection, that is quite cryptic in patients with antibiotic resistance.

Currently, even organisation with a non-life-threatening form of prostate cancer have their prostate removed, accept deviation diagnosis and turn sterilized from hormone treatment. We know that prostate diagnosis leaves many patients with a severely reduced peculiarity of life and poignant side effects such as incontinence, erectile dysfunction and basin – in some cases finale in suicide.

Preventing overtreatment is so a really critical aspect of a group’s goals.

Tessem is a fourth NTNU researcher in a Horizon 2020 investigate programme to accept this kind of ERC Starting Grant, and a initial female. The appropriation of EUR 1.5 million will be widespread over 5 years.


Explore further:
Body distance and prostate cancer risk

Journal reference:
British Journal of Cancer
search and some-more info
website

Provided by:
Norwegian University of Science and Technology
search and some-more info

website

feedback
feedback to editors

 

Related Posts

  • No Related Posts